171 related articles for article (PubMed ID: 34039407)
1. Common pathways and functional profiles reveal underlying patterns in Breast, Kidney and Lung cancers.
Romera-Giner S; Andreu Martínez Z; García-García F; Hidalgo MR
Biol Direct; 2021 May; 16(1):9. PubMed ID: 34039407
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis reveals disrupted pathways regulated by microRNAs in cancer.
Wilk G; Braun R
Nucleic Acids Res; 2018 Feb; 46(3):1089-1101. PubMed ID: 29294105
[TBL] [Abstract][Full Text] [Related]
5. A systems biology approach for miRNA-mRNA expression patterns analysis in non-small cell lung cancer.
Najafi A; Tavallaei M; Hosseini SM
Cancer Biomark; 2016; 16(1):31-45. PubMed ID: 26484609
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic studies provide insights into the tumor suppressive role of miR-146a-5p in non-small cell lung cancer (NSCLC) cells.
Iacona JR; Monteleone NJ; Lemenze AD; Cornett AL; Lutz CS
RNA Biol; 2019 Dec; 16(12):1721-1732. PubMed ID: 31425002
[TBL] [Abstract][Full Text] [Related]
7. Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.
Abadi AJ; Zarrabi A; Gholami MH; Mirzaei S; Hashemi F; Zabolian A; Entezari M; Hushmandi K; Ashrafizadeh M; Khan H; Kumar AP
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33670518
[TBL] [Abstract][Full Text] [Related]
8. MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
Cizeron-Clairac G; Lallemand F; Vacher S; Lidereau R; Bieche I; Callens C
BMC Cancer; 2015 Jul; 15():499. PubMed ID: 26141719
[TBL] [Abstract][Full Text] [Related]
9. Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
Oztemur Islakoglu Y; Noyan S; Aydos A; Gur Dedeoglu B
OMICS; 2018 Nov; 22(11):709-716. PubMed ID: 30388053
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs.
He H; Wang L; Zhou W; Zhang Z; Wang L; Xu S; Wang D; Dong J; Tang C; Tang H; Yi X; Ge J
PLoS One; 2015; 10(5):e0125672. PubMed ID: 25938468
[TBL] [Abstract][Full Text] [Related]
12. Identification of genes and pathways involved in kidney renal clear cell carcinoma.
Yang W; Yoshigoe K; Qin X; Liu JS; Yang JY; Niemierko A; Deng Y; Liu Y; Dunker A; Chen Z; Wang L; Xu D; Arabnia HR; Tong W; Yang M
BMC Bioinformatics; 2014; 15 Suppl 17(Suppl 17):S2. PubMed ID: 25559354
[TBL] [Abstract][Full Text] [Related]
13. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies.
Qi Y; Wang L; Wang K; Peng Z; Ma Y; Zheng Z; Shang D; Xu W; Zheng J
Biomed Pharmacother; 2019 Mar; 111():821-834. PubMed ID: 30616081
[TBL] [Abstract][Full Text] [Related]
14. Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti-lung cancer cell invasion.
Zhan JW; Jiao DM; Wang Y; Song J; Wu JH; Wu LJ; Chen QY; Ma SL
Thorac Cancer; 2017 Sep; 8(5):461-470. PubMed ID: 28660665
[TBL] [Abstract][Full Text] [Related]
15. Identification of circulating microRNA signatures for breast cancer detection.
Chan M; Liaw CS; Ji SM; Tan HH; Wong CY; Thike AA; Tan PH; Ho GH; Lee AS
Clin Cancer Res; 2013 Aug; 19(16):4477-87. PubMed ID: 23797906
[TBL] [Abstract][Full Text] [Related]
16. The miR-200 family as prognostic markers in clear cell renal cell carcinoma.
Saleeb R; Kim SS; Ding Q; Scorilas A; Lin S; Khella HW; Boulos C; Ibrahim G; Yousef GM
Urol Oncol; 2019 Dec; 37(12):955-963. PubMed ID: 31635993
[TBL] [Abstract][Full Text] [Related]
17. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
18. Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma.
Wang J; Li Z; Ge Q; Wu W; Zhu Q; Luo J; Chen L
J Thorac Cardiovasc Surg; 2015 May; 149(5):1404-14.e4. PubMed ID: 25813410
[TBL] [Abstract][Full Text] [Related]
19. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
[TBL] [Abstract][Full Text] [Related]
20. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
Hu S; Yuan Y; Song Z; Yan D; Kong X
Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
